目的 探究前列地尔联合倍他司汀治疗铂类化疗药物所致耳源性眩晕的疗效。方法 选取2017年8月—2019年11月河南科技大学第一附属医院收治的85例铂类化疗肿瘤患者且出现耳源性眩晕者，随机分为对照组（42例）和治疗组（43例）。对照组静脉滴注盐酸倍他司汀注射液，10 mg/次，1次/d。治疗组在对照组基础上静脉滴注前列地尔注射液，1 mL/次，1次/d。两组均治疗14 d。观察两组的临床疗效，比较两组眩晕障碍评定量表评分和生活质量评分。结果 治疗后，治疗组总有效率93.02%，显著高于对照组的76.19%（P<0.05）。治疗后，两组眩晕障碍评定量表评分均较治疗前显著降低，而生理机能、生理职能、情感职能评分均显著升高（P<0.05）；治疗后，治疗组眩晕障碍评定量表评分低于对照组，但生理机能、生理职能、情感职能评分高于对照组（P<0.05）。结论 前列地尔联合倍他司汀治疗铂类化疗药物所致耳源性眩晕疗效较好，可有效改善临床症状，提高了生活质量，具有一定的临床推广应用价值。

Objective To explore the clinical efficacy of alprostadil combined with betastastine in treatment of otogenic vertigo induced by platinum-class chemotherapy drugs. Methods A total of 85 patients with platinum-type chemotherapy tumor with otogenic vertigo admitted to the First Affiliated Hospital of Henan University of Science and Technology from August 2017 to November 2019 were selected and randomly divided into control group (42 cases) and treatment group (43 cases). Patients in the control group were iv administered with Betahistine Hydrochloride Injection, 10 mL/time, once daily. Patients in the treatment group were iv administered with Alprostadil Injection on the basis of the control group, 1 mL/time, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the vertigo disorder rating scale score and life quality score were compared between two groups. Results After treatment, the total effective rate of the treatment group was 93.02%, which was significantly higher than that of the control group (76.19%, P<0.05). After treatment, the scores of vertigo disorder rating scale in both groups were significantly decreased compared with before treatment, but the scores of physiological function, physiological function and emotional function were significantly increased (P<0.05). After treatment, the scores of vertigo disorder rating scale in the treatment group were lower than those in the control group, but the scores of physiological function, physiological function and emotional function in the treatment group were higher than those in the control group (P<0.05). Conclusion Alprostadil combined with betastastine has curative effect in treatment of otogenic vertigo induced by platinum-class chemotherapy drugs, and can effectively improve the clinical symptoms, and improve the life quality, which has a certain value of clinical application.

R971